Approved Risk Evaluation and Mitigation Strategies (REMS)
The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. Additional REMS Information.
The three tables below provide separate lists for:
- Currently Approved Individual REMS
- Currently Approved Single Shared System REMS
-- Extended-Release and Long-Acting (ER/LA) Opioid Analgesics REMS
-- Isotretinoin iPLEDGE REMS
-- Mycophenolate REMS
-- Rosiglitazone REMS New! -- Transmucosal Immediate-Release Fentanyl (TIRF) Products REMS
Currently Approved Individual REMS
Product | Application | Date REMS Approved | REMS Components (All REMS include timetable for assessment) |
---|---|---|---|
Actemra (tocilizumab) Injection (PDF - 2MB) | BLA 125276/49 | 1/8/2011; modified 4/15/2011, 6/20/2012, 10/11/2012 | communication plan |
Adasuve (loxapine) Inhalation Powder (PDF - 3.5MB) | NDA 22-549 | 12/21/2012 | communication plan, elements to assure safe use, implementation system |
Ampyra (dalfampridine) Extended-Release Tablets (PDF - 124KB) | NDA 22-250/S-004 | 1/22/2010; modified 11/17/2011; 7/20/2012 | communication plan |
Androgel (testosterone) Gel (PDF - 28KB) | NDA 21-015/S-032 | 9/18/2009; modified 3/10/2011, 11/30/2011 | medication guide |
Androgel (testosterone) 1.62% Gel (PDF - 65KB) | NDA 22-309/S-001 | 4/29/2011; modified 9/7/2012 | medication guide |
Aranesp (darbepoetin alfa) Injection (PDF - 11MB) | BLA 103951/5285 | 2/16/2010; modified 6/24/2011, 5/31/2012 | medication guide, communication plan, elements to assure safe use, implementation system |
Axiron (testosterone) Topical Solution (PDF - 37KB) | NDA 22-504/S-002 | 11/23/2010; modified 3/31/2011 | medication guide |
Brilinta (ticagrelor) Tablets (PDF - 238KB) Updated! | NDA 22-433/S-006 | 7/20/2011; modified 1/24/2013 | medication guide, communication plan |
Bydureon (exenatide) Extended-Release for Injectable Suspension (PDF - 116KB) | NDA 22-200 | 1/27/2012 | communication plan |
Caprelsa (vandetanib) Tablets (PDF - 6MB) | NDA 22-405/S-001 | 4/6/2011; modified 6/22/2011 | medication guide, communication plan, elements to assure safe use, implementation system |
Chantix (varenicline) Tablets (PDF - 17KB) | NDA 21-928/S-019, S-020, S-21 | 10/19/2009; modified 4/22/2010, 7/22/2011 | medication guide |
Darvon Capsules, Darvon-N Tablets, and Darvocet-N (propoxyphene) Tablets | NDA 10-997/S-051, S-052; 16-062/S-041, S-042; 17-122/S-061, S-062 | 9/25/2009 | medication guide |
Eliquis (apixaban) Tablets (PDF - 280KB) | NDA 202155 | 12/28/2012 | communication plan |
Entereg (alvimopan) Capsules (PDF - 1090KB) | NDA 21-775/S-007 | 5/20/2008 modified 2/5/2009, 9/25/2012 | communication plan, elements to assure safe use, implementation system |
Epogen/Procrit (epoetin alfa) Injection (PDF - 11MB) | BLA 103234/5281 | 2/16/2010; modified 6/24/2011, 5/31/2012 | medication guide, communication plan, elements to assure safe use, implementation system |
Extraneal (icodextrin) Intraperitoneal Solution (PDF - 2411KB) | NDA 21-321/S-020, S-021 | 3/8/2011 | medication guide, elements to assure safe use, implementation system |
Foradil (formoterol fumarate) Inhalation Powder (PDF - 306KB) | NDA 20-831/S-022 | 5/18/2011 | communication plan |
Forteo (teriparatide [rDNA origin]) Injection (PDF - 254KB) | NDA 21-318/S-027 | 7/22/2009; modified 3/13/2012 | medication guide, communication plan |
Fortesta (testosterone) Gel (PDF - 30KB) | NDA 21-463 | 12/29/2010 | medication guide |
Gattex (teduglutide [rDNA origin]) Injection (PDF - 946KB) | NDA 203441 | 12/21/2012 | communication plan, elements to assure safe use |
Gilenya (fingolimod) Capsules (PDF - 274KB) | NDA 22-527/S-005 | 9/21/2010; modifed 3/1/2012 | communication plan |
H.P. Acthar Gel (repository corticotropin) Injection (PDF - 56KB) | NDA 22-432 | 10/15/2010 | medication guide |
Juxtapid (lomitapide) Capsules (PDF - 2.5MB) | NDA 203858 | 12/21/2012 | elements to assure safe use, implementation system |
Kalbitor (ecallentide) Injection (PDF - 205KB) | BLA 125277/50 | 12/1/2009; modified 4/5/2011, 8/17/2011, 4/24/2012 | communication plan |
Krystexxa (pegloticase) Injection (PDF - 248KB) | BLA 125293/34, 40 | 9/14/2010; modified 10/19/2010, 4/16/2012 | communication plan |
Kynamro (mipomersen sodium) (PDF - 15MB) New! | NDA 203568 | 1/29/2013 | elements to assure safe use, implementation system |
Letairis (ambrisentan) Tablets (PDF - 2MB) | NDA 22-081/S-022 | 5/29/2009; modified 7/1/2009, 8/5/2009, 8/24/2010, 10/13/2010, 3/3/2011, 2/15/2012, 10/19/2012 | medication guide, elements to assure safe use, implementation system |
Lotronex (alosetron hydrochloride) Tablets (PDF - 18MB) | NDA 21-107/S-014 | 9/2/2010 | medication guide, elements to assure safe use, implementation system |
Lumizyme (alglucosidase alfa) (PDF - 848KB) | BLA 125291/79 | 5/24/2010; modified 9/12/2011, 7/16/2012 | communication plan, elements to assure safe use, implementation system |
Meridia (subutramine hydrochloride) Capsules | NDA 20-632/S-034, S-035 | 8/4/2010 | medication guide |
Metoclopramide Oral Solution (PDF - 31KB) | ANDA 74-703/S-007 | 9/15/2009 | medication guide |
Metoclopramide Oral Solution (PDF - 24KB) | ANDA 72-744/S-011 | 9/15/2009 | medication guide |
Metoclopramide Oral Solution (PDF - 24KB) | ANDA 71-402/S-008 | 9/16/2009 | medication guide |
Mifeprex (mifepristone) Tablets (PDF - 205KB) | NDA 20-687/S-014 | 6/8/2011 | medication guide, elements to assure safe use, implementation system |
Multaq (dronedarone) Tablets (PDF - 111KB) | NDA 22-425/S-016, S-017, S-018 | 7/1/2009; modified 2/11/2011, 8/5/2011, 6/13/2012, 9/7/2012 | medication guide, communication plan |
Nplate (romiplostim) for Subcutaneous Injection (PDF - 45KB) | BLA 125268/77 | 8/22/2008; modified 8/14/2009, 3/23/2010, 7/29/2011, 12/6/2011 | communication plan |
Nulojix (belatacept) (PDF - 946KB) | BLA 125288 | 6/15/2011 | medication guide, communication plan |
Omontys (peginesatide) Injection (PDF - 165KB) | NDA 202799 | 3/27/2012 | communication plan |
Potiga (ezogabine) Tablets (PDF - 524KB) | NDA 22-345/S-001 | 6/10/2011; modified 3/19/2012 | communication plan |
Prolia (denosumab) Injection (PDF - 129KB) | BLA 125320/53 | 6/1/2010; modified 9/16/2011, 5/10/2012 | medication guide, communication plan |
Promacta (eltrombopag) Tablets (PDF - 225KB) | NDA 22-291/S-006 | 11/20/2008; modified 3/5/2010, 2/25/2011, 12/6/2011 | communication plan |
Qsymia (phentermine and topiramate) Extended-Release Capsules (PDF - 3MB) | NDA 22-580/S-001 | 7/17/2012; modified 11/1/2012 | medication guide, elements to assure safe use, implementation system |
Revlimid (lenalidomide) Capsules (PDF - 2523KB) | NDA 21-880/S-031 | 8/3/2010; modified 5/9/2012 | medication guide, elements to assure safe use, implementation system |
Sabril (vigabatrin) Oral Solution and Tablets (PDF - 1.5MB) | NDA 22-006/S-006; 20-427/S-005 | 8/21/2009; modified 1/18/2011, 12/11/2012 | medication guide, communication plan, elements to assure safe use, implementation system |
Soliris (eculizumab) Injection (PDF - 3MB) | BLA 125166/172 | 6/4/2010; modified 9/23/2011 | medication guide, elements to assure safe use |
Stelara (ustekinumab) Injection (PDF - 347KB) | BLA 125261/63 | 9/25/2009; modified 12/30/2009, 10/20/2010, 5/2/2012 | communication plan |
Suboxone (buprenorphine and naloxone) Sublingual Film (PDF - 960KB) | NDA 22-410 | 8/30/2010 | medication guide, elements to assure safe use, implementation system |
Suboxone (buprenorphine and naloxone) Sublingual Tablets (PDF - 455KB) | NDA 22-733/S-007, S-008 | 12/22/2011 | medication guide, elements to assure safe use, implementation system |
Subutex (buprenorphine) Sublingual Tablets (PDF - 467KB) | NDA 20-732/S-006, S-007 | 12/22/2011 | medication guide, elements to assure safe use, implementation system |
Tapentadol Tablets (PDF - 222KB) | NDA 22-304 | 11/20/2008 | medication guide |
Tasigna (nilotinib) Capsules (PDF - 4MB) | NDA 22-068/S-008, S-009 | 3/15/2010; modified 6/17/2010, 1/14/2011, 10/26/2011, 11/18/2011 | medication guide, communication plan |
Testim (testosterone) Gel (PDF - 35KB) | NDA 21-454/S-014 | 9/18/2009; modified 11/22/2011 | medication guide |
Testosterone Gel (PDF - 13KB) | NDA 202763 | 2/14/2012 | medication guide |
Thalomid (thalidomide) Capsules (PDF - 5402KB) | NDA 20-785/S-039 | 8/3/2010 | medication guide, elements to assure safe use, implementation system |
Tikosyn (dofetilide) Capsules (PDF - 2MB) | NDA 20-931/S-003 | 7/11/2011 | medication guide, elements to assure safe use, implementation system |
Tracleer (bosentan) Tablets (PDF - 1000KB) | NDA 21-290/S-018 | 8/7/2009; modified 2/19/2010 | medication guide, elements to assure safe use, implementation system |
Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets (PDF - 9MB) | NDA 21-752/S-030 | 7/16/2012 | medication guide, elements to assure safe use |
Tysabri (natalizumab) Intravenous Injection (PDF - 65KB) | BLA 125104/576 | 10/7/2011; modified 1/20/2012 | medication guide, elements to assure safe use, implementation system |
Vibativ (telavancin) Injection (PDF - 133KB) | NDA 22-110/S-002 | 9/11/2009; modified 7/27/2011 | medication guide, communication plan |
Victoza (liraglutide) Injection (PDF - 1025KB) | NDA 22-341/S-004 | 1/25/2010; modified 5/18/2011 | communication plan |
Vivitrol (naltrexone) Extended-Release Injectable Suspension (PDF - 27KB) | NDA 21-897/S-015 | 3/22/2010; modified 10/12/2010 | medication guide |
Xarelto (rivaroxaban) Tablets (PDF - 438KB) | NDA 202439/S-005 | 11/4/2011; modified 7/12/2012 | communication plan |
Xeljanz (tofacitinib) Tablets (PDF - 161KB) | NDA 203214 | 11/6/2012 | medication guide, communication plan |
Xenazine (tetrabenazine) Tablets (PDF - 1011KB) | NDA 21-894/S-007 | 8/15/2008; modified 12/1/2009, 5/4/2011, 8/17/2012 | communication plan |
Xiaflex (collagenase clostridium histolyticum) Injection (PDF - 2MB) | BLA 125338/40 | 2/2/2010; modifed 2/24/2012 | communication plan |
Yervoy (ipilimumab) Injection (PDF - 3MB) | BLA 125377/16 | 3/25/2011; modified 2/16/2012 | communication plan |
Zyban (bupropion hydrochloride) Sustained-Release Tablets (PDF - 19KB) | NDA 20-711/S-034 | 2/26/2010 | medication guide |
Zyprexa Relprevv (olanzapine) Extended-Release Injection (PDF - 3.5MB) | NDA 22-173/S-008, S-010, S-014 | 12/11/2009; modified 7/8/2010, 8/3/2012 | medication guide, communication plan, elements to assure safe use, implementation system |
Currently Approved Single Shared System REMS
Name of Shared System REMS (and included products) | Date REMS Approved | REMS Components (All REMS include timetable for assessment) |
---|---|---|
Extended-Release and Long-Acting Opioid Analgesics REMS (PDF - 1.3MB) | 7/9/2012; modified 8/28/2012 | medication guide, elements to assure safe use |
Isotretinoin iPLEDGE REMS (PDF - 315KB)
| 10/22/2010 | medication guide, elements to assure safe use, implementation system |
Mycophenolate REMS (PDF - 5MB)
| 9/25/2012 | medication guide, elements to assure safe use |
Rosiglitazone REMS (PDF - 1.2MB) New!
| 1/25/2013 | medication guide, elements to assure safe use, implementation system |
Transmucosal Immediate-Release Fentanyl (TIRF) Products (PDF - 900KB)
| 12/28/2011; modified 6/5/2012 | medication guide, elements to assure safe use, implementation system |
Released REMS
Product | Date Released from REMS Requirement |
---|---|
Actonel (risedronate sodium) Tablets | 8/22/2011 |
Actonel with Calcium (risedronate sodium and calcium carbonate) Tablets | 8/22/2011 |
Actoplus Met (pioglitazone hydrochloride and metformin hydrochloride) Tablets | 5/17/2012 |
Actoplus Met XR (pioglitazone and metformin) Extended-Release Tablets | 5/17/2012 |
Actos (pioglitazone hydrochloride) Tablets | 5/17/2012 |
Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder) | 8/9/2012 |
Advair HFA (fluticasone propionate and salmeterol xinafoate inhalation powder) | 8/9/2012 |
Aplenzin (buproprion hydrobromide) Extended-Release Tablets | 4/29/2011 |
Arcapta Neohaler (indacaterol maleate) Inhalation Powder | 12/18/2012 |
Atelvia (risedronate sodium) Delayed-Release Tablets | 8/22/2011 |
Avelox (moxifloxacin) Tablets and I.V. Solution | 8/3/2011 |
Banzel (rufinamide) Tablets and Oral Suspension | 6/10/2011 |
Boniva (ibandronate sodium) Injection | 7/1/2011 |
Boniva (ibandronate sodium) Tablets | 7/1/2011 |
Botox/Botox Cosmetic (onabotulinumtoxinA) Injection | 7/16/2012 |
Brovana (arformoterol tartrate) Inhalation Solution | 8/9/2012 |
Byetta (exanatide) Injection | 8/5/2011 |
Cambia (diclofenac potassium) Oral Solution | 7/20/2011 |
Carbatrol (carbamazepine) Extended-Release Capsules | 8/22/2011 |
Celontin (methsuximide) Capsules | 6/15/2011 |
Cimzia (certolizumab pegol) Lyophilized powder for solution for subcutaneous injection | 7/26/2011 |
Cipro (ciprofloxacin) Tablets, Oral Suspension, I.V. Solution , and Extended-Release Tablets | 8/3/2011 |
Colcrys (colchicine) Tablets | 7/20/2011 |
Colcrys (colchicine) Tablets | 7/20/2011 |
Colcrys (colchicine) Tablets | 7/20/2011 |
Copegus (ribavirin) Tablets | 5/9/2011 |
Creon (pancrelipase) Delayed-Release Capsules | 5/9/2011 |
Dilantin (phenytoin) Oral Suspension | 5/27/2011 |
Duetact (pioglitazone hydrochloride and glimepiride) Tablets | 5/17/2012 |
Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol | 11/27/2012 |
Dysport (abobotulinumtoxinA) Injection | 5/22/2012 |
Edluar (zolpidem tartrate) Sublingual Tablets | 8/10/2011 |
Effient (prasugrel) Tablets | 3/23/2012 |
Enbrel (etanercept) for Subcutaneous Injection | 8/10/11 |
Epzicom (abacavir sulfate and lamivudine) Tablets | 5/13/2011 |
Equetro (carbamazepine) Extended-Release Capsules | 1/27/2012 |
Extavia (interferon beta-1b) | 6/22/2011 |
Factive (gemifloxacin) Tablets | 8/4/2011 |
Fosamax (alendronate sodium) Oral Solution and Tablets | 7/1/2011 |
Fosamax Plus D (alendronate sodium and cholecalciferol) Tablets | 7/1/2011 |
Gabitril (tiagabine hydrochloride) Tablets | 1/25/2012 |
Gralise (gabapentin) Tablets | 4/28/2011 |
HalfLytely Bisacodyl Bowel Prep Kit (bisacodyl, polyethylene glycol 3500, potassium chloride, sodium bicarbonate, sodium chloride) | 7/6/2011 |
Humira (adalimumab) Injection | 12/13/2011 |
Infergen (interferon alfacon-1) | 6/1/2011 |
Intron A (interferon alfa-2b) | 5/13/2011 |
Invirase (saquinavir mesylate) Capsules and Tablets | 5/26/2011 |
Janumet (sitagliptin/metformin) Tablets | 4/14/2011 |
Januvia (sitagliptin) Tablets | 4/14/2011 |
Kaletra (lopinavir and ritonavir) Tablets and Oral Solution | 5/6/2011 |
Keppra, Keppra XR (levetiracetam) Tablets, Extended-Release Tablets, Oral Solution, and Injection | 8/10/2011 |
Ketek (telithromycin) Tablets | 6/20/2011 |
Klonopin (clonazepam) Tablets and Orally Disintegrating Tablets | 11/29/2011 |
Lamictal (lamotrigine) Tablets, Chewable Dispersible Tablets, and Orally Disintegrating Tablets (ODT) | 5/31/2011 |
Lamictal XR (lamotrigine) Extended-Release Tablets | 4/25/2011 |
Lariam (mefloquine hydrochloride) Tablets | 4/29/2011 |
Levaquin (levofloxacin) Tablets, Injection, and Oral Solution | 10/7/2011 |
Lyrica (pregabalin) Capsules and Oral Solution | 4/26/2011 |
Metoclopramide Oral Solution (ANDA 73-680) | 3/14/2012 |
Metozolv ODT (metoclopramide hydrochloride) Orally Disintegrating Tablets | 8/22/2011 |
Morphine Sulfate Oral Solution | 10/18/2011 |
Myobloc (rimabotulinumtoxinB) Injection | 6/13/2012 |
Mysoline (primidone) Tablets | 8/10/2011 |
Neurontin (gabapentin) Capsules, Tablets, and Oral Solution | 8/10/2011 |
Noroxin (norfloxacin) Tablets | 9/8/2011 |
Nuvigil (armodafinil) Tablets | 1/13/2012 |
Oleptro (trazadone hydrochloride) Extended-Release Tablets | 5/11/2011 |
Osmoprep (sodium phosphate, dibasic anhydrous and sodium phosphate, monobasic, monohydrate) Tablets | 12/9/2011 |
Oxycodone Hydrochloride Oral Solution | 1/25/2012 |
Pancreaze (pancrelipase) Delayed-Release Capsules | 6/20/2011 |
Peganone (ethotoin) Tablets | 5/31/2011 |
Pegasys (peginterferon alfa-2a) | 5/9/2011 |
PegIntron (peginterferon alfa-2b) | 5/13/2011 |
PegIntron Rebetol Combopack (peginterferon alfa-2b, Redipen Single-dose Delivery System and Rebetol ribavirin) | 8/18/2009 |
Pennsaid (diclofenac sodium) Topical Solution | 7/14/2011 |
Plavix (clopidogrel bisulfate) Tablets | 5/3/2011 |
Perforomist (formoterol fumarate) Inhalation Solution | 9/25/2012 |
Pradaxa (dabigatran etexilate mesylate) Capsules | 4/5/2011 |
Propylthiouracil (propylthiouracil) Tablets | 7/27/2011 |
Proquin XR (ciprofloxacin) Extended-Release Tablets | 8/15/2011 |
Provigil (modafinil) Tablets | 1/13/2012 |
Qualaquin (quinine sulfate) Capsules | 5/22/2012 |
Rapamune (sirolimus) Oral Solution and Tablets | 6/6/2011 |
Rebetol (ribivarin) Capsules and Oral Solution | 4/19/2011 |
Reclast (zoledronic acid) Injection | 8/15/2011 |
Reglan ODT (metoclorpramide hydrochloride) Orally Disintegrating Tablets | 8/2/2011 |
Reglan (metoclopramide hydrochloride) Tablets | 8/2/2011 |
Regranex (becaplermin) | 4/30/2012 |
Remicade (infliximab) Vial | 8/1/2011 |
Roferon-A Interferon (alfa-2a, recombinant) Injection | 6/16/2011 |
Rozerem (ramelteon) Tablets | 8/4/2011 |
Samsca (tolvaptan) Tablets | 9/14/2012 |
Savella (milnacipran hydrochloride) Tablets | 4/26/2011 |
Serevent Diskus (salmeterol xinafoate) Inhalation Powder | 8/9/2012 |
Seroquel (quetiapine) Tablets | 11/9/2011 |
Seroquel XR (quetiapine) Extended-Release Tablets | 11/9/2011 |
Silenor (doxepin) Tablets | 10/30/2011 |
Simponi (golimumab) Injection | 3/17/2011 |
Sucraid (sacrosidase) Oral Solution | 12/9/2010 |
Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate) Oral Solution | 7/6/2011 |
Sutent (sunitinib) Capsules | 5/19/2011 |
Symbicort (budesonide and formoterol) Inhalation Aerosol | 7/23/2012 |
Symbyax (olanzapine and fluoxetine) Capsules | 6/21/2011 |
Tegretol and Tegretol-XR (carbemazepine) Tablets, ChewableTablets, Suspension, and Extended-Release Tablets | 10/30/2011 |
Topamax (topiramate) Tablets and Sprinkle Capsules | 6/27/2011 |
Tranxene (clorazepate dipotassium) Tablets | 7/19/2011 |
Treximet (sumatriptan succinate and naproxen sodium) Tablets | 9/23/2011 |
Trileptal (oxcarbazepine) Tablets and Suspension | 10/30/2011 |
Trilipix (fenofibric acid) Delayed-Release Capsules | 9/30/2011 |
Trizivir (abacavir sulfate, lamivudine, and zidovudine) Tablets | 5/13/2011 |
Tyzeka (telbivudine) Oral Solution | 5/5/2011 |
Tyzeka (telbivudine) Tablets | 5/5/2011 |
Venlafaxine hydrochloride Extended- Release Tablets | 7/31/2012 |
Videx, Videx EC (didanosine) Delayed-Release Capsules and Oral Solution | 5/10/2011 |
Viibryd (vilazodone hydrochloride) Tablets | 6/29/2011 |
Vimpat (lacosamide) Injection, Oral Solution, and Tablets | 8/10/2011 |
Viramune (nevirapine) Tablets, Oral Suspension, and Extended-Release Tablets | 5/6/2011 |
Visicol (sodium phosphate, dibasic anhydrous and sodium phosphate, monobasic, monohydrate)Tablets | 12/9/2011 |
Votrient (pazopanib) Tablets | 4/21/2011 |
Wellbutrin, Wellbutrin SR (bupropion hydrochloride) Tablets and Sustained-Release Tablets | 8/2/2012 |
Wellbutrin XL (bupropion hydrochloride) Extended-Release Tablets | 8/2/2012 |
Xeomin (incobotulinumtoxinA) Injection | 7/16/2012 |
Xolair (omalizumab) Injection | 12/22/2011 |
Zarontin (ethosuximide) Capsules | 6/15/2011 |
Zenpep (pancrelipase) Delayed-Release Capsules | 6/10/2011 |
Zerit (stavudine) Capsules and Oral Solution | 5/11/2011 |
Ziagen (abacavir sulfate) Tablets and Oral Solution | 5/13/2011 |
Zipsor (diclofenac potassium) Capsules | 5/4/2011 |
Zolpimist (zolpidem tartrate) Oral Spray | 9/28/2011 |
Zonegran (zonisamide) Capsules | 5/27/2011 |
Zortress (everolimus) Tablets | 5/2/2012 |
Zyprexa, Zyprexa Zydis (olanzapine) Tablets | 6/21/2011 |
-
More Information on Single Shared System REMS
-
-
Additional REMS Resources
- REMS Assessments: Social Science Methodologies to Assess Goals Related to Knowledge: Public Workshop, 6/7/2012
- FDA Issue Paper on REMS Assessments, June 7, 2012 (PDF - 96KB)
- Guidance for Industry: Medication Guides — Distribution Requirements and Inclusion in REMS (PDF - 91KB)
Final version (11/2011) - Questions and Answers on Draft Guidance for Industry: Medication Guides - Distribution Requirements and Inclusion in REMS
3/2011 - Format and Content of Proposed REMS, REMS Assessments, and Proposed REMS Modifications (PDF - 316KB)
Guidance for Industry (9/2009)
No hay comentarios:
Publicar un comentario